Aba Chemicals Corporation(300261) announced on the evening of January 16 that due to the recent abnormal fluctuation of the company’s share price, the company will verify the abnormal fluctuation of stock trading. The trading of the company’s shares has been suspended since the opening of the market on January 17 and resumed after the disclosure of the verification announcement.
According to the announcement, Aba Chemicals Corporation(300261) share price deviated by 30% from the closing price for two consecutive trading days on January 13 and January 14, 2022, which belongs to abnormal fluctuation of stock trading.
Previously, due to the cumulative deviation of the closing price of the stock price for seven consecutive trading days from December 20, 2021 to December 28, 2021, the trading of Aba Chemicals Corporation(300261) was suspended from the opening of the market on December 29, 2021 and resumed from the opening of the market on January 6, 2022.
Aba Chemicals Corporation(300261) in the announcement on the verification results and resumption of trading of the company’s shares disclosed on January 5, the company said that the company had not signed any cooperation agreement with Pfizer, had no cooperative relationship with Pfizer, and did not supply carlon anhydride and its derivatives to Pfizer. The customers of the company’s carbonic anhydride and its derivatives are mainly Chinese customers and Indian customers. It is uncertain whether the company’s carbonic anhydride and its derivatives are indirectly supplied to Pfizer. Remind investors to pay attention to investment risks.
The company also said that as of December 31, 2021, its sales revenue of carbonic anhydride and its derivatives in 2021 was 27.073 million yuan (excluding tax), accounting for 1% – 2% of the company’s total operating revenue in 2021, which is not expected to have a significant impact on the performance in 2021; As of December 31, 2021, the total amount of orders on hand of the company’s carbonic anhydride and its derivatives was 63.5408 million yuan (excluding tax), which is not expected to have a significant impact on the performance in 2022.
